Phase II multicenter, single arm, open label study of nivolumab in combination with ipilimumab in untreated patients with metastatic uveal melanoma (GEM1402.NCT02626962)

被引：0

作者：

Piulats Rodriguez, M. ^{[1
]}

de la Cruz-Merino, L. ^{[2
]}

Espinosa, E. ^{[3
]}

Alonso Carrion, L. ^{[4
]}

Martin Algarra, S. ^{[5
]}

Lopez-Castro, R. ^{[6
]}

Curiel Garcia, M. T. ^{[7
]}

Rodriguez Abreu, D. ^{[8
]}

Rullan Iriarte, A. J. ^{[9
]}

Berrocal Jaime, A. ^{[10
]}

机构：

[1] ICO, Med Oncol, Barcelona, Spain

[2] Hosp Univ Virgen Macarena, Oncol, Seville, Spain

[3] Hosp Univ La Paz, Oncol, Madrid, Spain

[4] Univ Malaga, Oncol, Malaga, Spain

[5] Clin Univ Navarra, Oncol, Navarra, Spain

[6] Hosp Univ Clin Valladolid, Med Oncol, Valladolid, Spain

[7] Hosp Univ Clin Santiago, Oncol, Santiago De Compostela, Spain

[8] Hosp Insular Canarias, Oncol, Las Palmas Gran Canaria, Spain

[9] Inst Catala Oncol, Oncol, Barcelona, Spain

[10] Hosp Gen Univ Valencia, Med Oncol, Valencia, Spain

来源：

ANNALS OF ONCOLOGY | 2018年 / 29卷

关键词：

D O I：

暂无

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

1247PD

引用

页码：444 / 444

页数：1

共 50 条

[21] Concomitant use of pembrolizumab and entinostat in adult patients with metastatic uveal melanoma (PEMDAC study): protocol for a multicenter phase II open label study
Jespersen, Henrik
Bagge, Roger Olofsson
Ullenhag, Gustav
Carneiro, Ana
Helgadottir, Hildur
Ljuslinder, Ingrid
Levin, Max
All-Eriksson, Charlotta
Andersson, Bengt
Stierner, Ulrika
Nilsson, Lisa M.
Nilsson, Jonas A.
Ny, Lars
BMC CANCER, 2019, 19 (1)
[22] Nivolumab With or Without Ipilimumab in Patients With Recurrent or Metastatic Merkel Cell Carcinoma: A Nonrandomized, Open-Label, International, Multicenter Phase I/II Study
Bhatia, Shailender
Topalian, Suzanne L.
Sharfman, William
Meyer, Tim
Steven, Neil
Lao, Christopher D.
Farinas-Madrid, Lorena
Devriese, Lot A.
Moore, Kathleen
Ferris, Robert L.
Honma, Yoshitaka
Elias, Ileana
Srirangam, Anjaiah
Garnett-Benson, Charlie
Lee, Michelle
Nghiem, Paul
JOURNAL OF CLINICAL ONCOLOGY, 2025, 43 (09)
[23] Sequencing of Ipilimumab Plus Nivolumab and Encorafenib Plus Binimetinib for Untreated BRAF-Mutated Metastatic Melanoma (SECOMBIT): A Randomized, Three-Arm, Open-Label Phase II Trial
Ascierto, Paolo A. A.
Mandala, Mario
Ferrucci, Pier Francesso
Guidoboni, Massimo
Rutkowski, Piotr
Ferraresi, Virginia
Arance, Ana
Guida, Michele
Maiello, Evaristo
Gogas, Helen
Richtig, Erika
Fierro, Maria Teresa
Lebbe, Celeste
Helgadottir, Hildur
Queirolo, Paola
Spagnolo, Francesco
Tucci, Marco
Del Vecchio, Michele
Gonzales Cao, Maria
Minisini, Alessandro Marco
De Placido, Sabino
Sanmamed, Miguel F. F.
Mallardo, Domenico
Curvietto, Marcello
Melero, Ignacio
Palmieri, Giuseppe
Grimaldi, Antonio M.
Giannarelli, Diana
Dummer, Reinhard
Sileni, Vanna Chiarion
JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (02) : 212 - +
[24] GRAY-B: An open label multicenter phase-2 GEM study on ipilimumab and radiation in patients with melanoma and brain metastases
Lopez Martin, J. A.
de la Cruz-Merino, Luis
Arance Fernandez, A. M.
Illescas, A.
Valduviecu Ruiz, I.
Berrocal, A.
Lopez-Torrecilla, J.
Marquez Rodas, I.
Soriano Teruel, M. V.
Alvarez Gonzalez, A.
Chust Vicente, M. L.
Rodriguez Abreu, D.
Cabrera, R.
Penas Sanchez, M. C.
Curiel, T.
Munoz Couselo, E.
Aristu, J. J.
Gomez-Caamano, A.
Medina Martinez, J.
Martin-Algarra, S.
ANNALS OF ONCOLOGY, 2016, 27
[25] Tucidinostat plus toripalimab in patients with unresectable or metastatic melanoma: An open-label, single-arm phase II study
Mao, Lili
Dai, Jie
Bai, Xue
Kong, Yan
Sheng, Xinan
Chi, Zhihong
Cui, Chuanliang
Lian, Bin
Tang, Bixia
Yan, Xieqiao
Wang, Xuan
Li, Siming
Zhou, Li
Wei, Xiaoting
Li, Juan
Li, Caili
Duan, Rong
Xu, Huayan
Guo, Jun
Si, Lu
JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
[26] Safety and efficacy of nivolumab in patients with rare melanoma subtypes who progressed on or after ipilimumab treatment: a single-arm, open-label, phase II study (CheckMate 172)
Nathan, Paul
Ascierto, Paolo A.
Haanen, John
Espinosa, Enrique
Demidov, Lev
Garbe, Claus
Guida, Michele
Lorigan, Paul
Chiarion-Sileni, Vanna
Gogas, Helen
Maio, Michele
Fierro, Maria Teresa
Hoeller, Christoph
Terheyden, Patrick
Gutzmer, Ralf
Guren, Tormod K.
Bafaloukos, Dimitrios
Rutkowski, Piotr
Plummer, Ruth
Waterston, Ashita
Kaatz, Martin
Mandala, Mario
Marquez-Rodas, Ivan
Munoz-Couselo, Eva
Dummer, Reinhard
Grigoryeva, Elena
Young, Tina C.
Schadendorf, Dirk
EUROPEAN JOURNAL OF CANCER, 2019, 119 : 168 - 178
[27] Ipilimumab plus nivolumab for patients with metastatic uveal melanoma: a multicenter, retrospective study (vol 8, e000331, 2020)
Najjar, Y. G.
Navrazhina, K.
Ding, F.
Puzanov, Igor
JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2020, 8 (02)
[28] Efficacy and Safety of the Melphalan/Hepatic Delivery System in Patients with Unresectable Metastatic Uveal Melanoma: Results from an Open-Label, Single-Arm, Multicenter Phase 3 Study
Zager, Jonathan S.
Orloff, Marlana
Ferrucci, Pier Francesco
Choi, Junsung
Eschelman, David J.
Glazer, Evan S.
Ejaz, Aslam
Howard, J. Harrison
Richtig, Erika
Ochsenreither, Sebastian
Reddy, Sunil A.
Lowe, Michael C.
Beasley, Georgia M.
Gesierich, Anja
Bender, Armin
Gschnell, Martin
Dummer, Reinhard
Rivoire, Michel
Arance, Ana
Fenwick, Stephen William
Sacco, Joseph J.
Haferkamp, Sebastian
Weishaupt, Carsten
John, Johnny
Wheater, Matthew
Ottensmeier, Christian H.
ANNALS OF SURGICAL ONCOLOGY, 2024, 31 (08) : 5340 - 5351
[29] Phase II study of the frontline combination of ipilimumab and temozolomide in patients with metastatic melanoma.
Patel, Sapna Pradyuman
Hwu, Wen-Jen
Kim, Kevin B.
Papadopoulos, Nicholas E.
Hwu, Patrick
Radvanyi, Laszlo George
Mahoney, Sandy
Deburr, Tawania L.
Liu, Ping
Bedikian, Agop Y.
JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (15)
[30] Preliminary safety and efficacy results from an open-label, multicenter, phase 1 study of RP2 as a single agent and in combination with nivolumab in a cohort of patients with uveal melanoma.
Sacco, Joseph J.
Harrington, Kevin Joseph
Olsson-Brown, Anna
Chan, Tze Y.
Nenclares, Pablo
Leslie, Isla
Bommareddy, Praveen
Xie, Ben
Wolff, Johannes
Middleton, Mark R.
JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)

← 1 2 3 4 5 →